Added benefit of saxagliptin as monotherapy not proven

Thursday, December 5, 2013 - 19:00 in Health & Medicine

Although the drug manufacturer presented studies for an indirect comparison with sulfonylurea, these were unsuitable because they did not investigate the right patient group. The added benefit of saxaglipton as a monotherapy has not been proven.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net